MED — Stock Film
STOCK FILMSCENE 1/11MED · $10.62
Stock Expert AI presents
MED
Medifast, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Medifast, Inc. A quick introduction.

On the stock market since 1993, it operates in the world of consumer spending. It has 504 employees. Now — the numbers.

on the stock market since 1993
504 employees
$118.1M market value
Revenue last year:
$0
The loss that same year:
$0
Sales don’t cover the costs; the gap drains from the cash pile every year.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

WHERE DOES THE MONEY COME FROM?
85%Optavia
Optavia 85%Medifast Direct 11%Franchise Weight Control Centers 4%Medifast Wholesale Physicans <1%
85% of all revenue comes from a single line: Optavia.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

THE SALES TREND
Sales have been shrinking.

An average decline of 29% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.

$1.5B
2021
$1.6B
2022
$1.1B
2023
$602.5M
2024
$385.8M
2025
In the vault right now:
$0
DEBT: $16.8M
At this pace, that money lasts about 9 years.

Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
41
weak

Clearly below the class average.

FINANCIAL STRENGTH
96
very strong

Debt is low and cash is strong; the finances stand solid.

VALUATION
57
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
3
very weak

Clearly below the class average.

PRICE MOMENTUM
31
very weak

Clearly below the class average.

WORTH WATCHING

Growth: Sales growth trails the sector average.

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 96% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Strong cash, light debt

There is $167.3M in the vault; even if every debt were paid off, $150.5M would remain.

2
THE BRIGHT SIDE · 2/2
Executives are buying their own stock

Over the last 12 months, company executives reported 28 buys and 18 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/3
Small scale, thin loss

A loss of $18.7M against $385.8M in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/3
Growth trails the sector

The growth engine is running at low revs right now. Report-card grade: 3/100.

3
THE RISKS · 3/3
The stock has lost its spark

Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 31/100. For a turnaround signal, the stock first needs to close the gap with the market.

FINALE · THE GRADE
D
0 / 100 · MoonshotScore

On our five-subject report card, MED sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: MED is a small company that closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film